Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1764167 | 0.72 | MTOR (0.39) | MTORRAB9AGRM7TSHRCYP3A4 | |
| SCHEMBL1764563 | 0.71 | TSHR (0.41) | MTORRAB9AGRM7TSHRCYP3A4 | |
| SCHEMBL8858822 | 0.70 | LMNA (0.44) | TSHRCYP2D6SRCLMNAMAPK1 | |
| SCHEMBL9540931 | 0.70 | LMNA (0.44) | TSHRCYP2D6SRCLMNAMAPK1 | |
| SCHEMBL1764562 | 0.70 | MTOR (0.61) | MTORRAB9AGRM7TSHRCYP3A4 | |
| SCHEMBL9242052 | 0.69 | SRC (0.44) | CYP2D6SRCLMNAHDAC3HDAC4 | |
| SCHEMBL5200301 | 0.68 | LMNA (0.43) | TSHRCYP2D6SRCLMNAMAPK1 | |
| Ammonia Solution, Strong SCHEMBL9515772 | 0.68 | LMNA (0.43) | TSHRCYP2D6SRCLMNAMAPK1 | |
| Ammonia Solution, Strong SCHEMBL21495185 | 0.68 | LMNA (0.43) | TSHRCYP2D6SRCLMNAMAPK1 | |
| Water SCHEMBL21046213 | 0.68 | LMNA (0.43) | TSHRCYP2D6SRCLMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9279085-B2 | Method for the production of monofunctionalized dialkylphosphinic acids, esters and salts, and use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2016-03-08 | — | — | US | disclosed |
| EP-2379572-B1 | METHOD FOR THE PRODUCTION OF MONOFUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS, ESTERS, AND SALTS, AND USE THEREOF | CLARIANT INT LTD (CH) | 2015-12-23 | — | — | EP | disclosed |
| EP-2379572-A1 | METHOD FOR THE PRODUCTION OF MONOFUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS, ESTERS, AND SALTS, AND USE THEREOF | Clariant International Ltd. (CH) | 2011-10-26 | — | — | EP | disclosed |
| US-20110251315-A1 | Method for the Production of Monofunctionalized Dialkylphosphinic Acids, Esters and Salts, and Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-10-13 | — | — | US | disclosed |
| WO-2010069420-A1 | METHOD FOR THE PRODUCTION OF MONOFUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS, ESTERS, AND SALTS, AND USE THEREOF | CLARIANT INTERNATIONAL LTD (CH) | 2010-06-24 | — | — | WO | disclosed |
| EP-0649426-B1 | INHIBITORS OF RETROVIRAL PROTEASES | AVENTIS PHARMA GMBH (DE) | 2001-09-26 | — | — | EP | disclosed |
| US-5663139-A | VIRICIDE OLIGOPEPTIDES | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-09-02 | — | — | US | disclosed |
| EP-0649426-A1 | INHIBITORS OF RETROVIRAL PROTEASES | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-04-26 | — | — | EP | disclosed |
| WO-1994000461-A1 | INHIBITORS OF RETROVIRAL PROTEASES | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251315-A1 | Method for the Production of Monofunctionalized Dialkylphosphinic Acids, Esters and Salts, and Use Thereof | LPAR6, LPAR2, HAO2 | MTOR 4127/4885RAB9A 3280/4885GRM7 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.